Sponsor Directory

Genentech, Inc. clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1397

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Chronic Lymphocytic Leukemia, 17p Deletion, Cancer of the Blood and Bone Marrow
Interventions: ABT-199 (Main Cohort), ABT-199 (Safety Expansion Cohort); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 16
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 11 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ixabepilone, Carboplatin, Bevacizumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 13
States / cities: Fort Myers, Florida • Gainesville, Florida • Terre Haute, Indiana + 10 more

Conditions: Rectal Cancer, Cancer of the Rectum, Colorectal Cancer
Interventions: 5-Fluorouracil, Bevacizumab, Radiation Therapy, Oxaliplatin, Leucovorin; Drug · Procedure
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 14
States / cities: Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 11 more

Conditions: Glioblastoma Multiforme
Interventions: Radiation therapy, Temozolomide, Bevacizumab, Everolimus; Radiation · Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 13
States / cities: Huntsville, Alabama • Fort Myers, Florida • Gainesville, Georgia + 10 more

Conditions: Metastatic Breast Cancer
Interventions: Pertuzumab, Trastuzumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 16
States / cities: Tucson, Arizona • Duarte, California • Stanford, California + 13 more

Conditions: Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma
Interventions: Venetoclax, AMG 176; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • Iowa City, Iowa + 6 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Carboplatin, Paclitaxel, Bevacizumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Fort Lauderdale, Florida • Terre Haute, Indiana • Louisville, Kentucky + 3 more

Conditions: Metastatic Melanoma
Interventions: Bevacizumab, Everolimus; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 15
States / cities: Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 12 more

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Bevacizumab, Anastrozole, Fulvestrant; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 11
States / cities: Fort Myers, Florida • Jacksonville, Florida • Orlando, Florida + 8 more

Conditions: Intracranial Meningioma
Interventions: Everolimus, Bevacizumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 7
States / cities: Orlando, Florida • Louisville, Kentucky • Omaha, Nebraska + 4 more

Conditions: Lung Cancer
Interventions: Bevacizumab, Pemetrexed, Radiotherapy, Folic Acid, vitamin B12, carboplatin; Drug · Procedure · Other
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 7
States / cities: Gainesville, Florida • Lakeland, Florida • Marietta, Georgia + 4 more

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN, Zidovudine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 10
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 4 more

About this Genentech, Inc. sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Genentech, Inc. is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Genentech, Inc. trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Genentech, Inc. clinical trials

Filter and sort this sponsor

Live official records

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer

5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer

RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM

A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC

RAD001 Plus Bevacizumab in Metastatic Melanoma

Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer

Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3

About this Genentech, Inc. sponsor directory page